Sutro Biopharma Inc (NASDAQ: STRO)’s stock price has gone decline by -12.88 in comparison to its previous close of 3.96, however, the company has experienced a -17.07% decrease in its stock price over the last five trading days. zacks.com reported 2024-11-13 that Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to loss of $0.81 per share a year ago.
Is It Worth Investing in Sutro Biopharma Inc (NASDAQ: STRO) Right Now?
STRO has 36-month beta value of 1.20. Analysts have mixed views on the stock, with 7 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for STRO is 75.97M, and currently, short sellers hold a 3.16% ratio of that float. The average trading volume of STRO on November 15, 2024 was 602.74K shares.
STRO’s Market Performance
STRO stock saw a decrease of -17.07% in the past week, with a monthly decline of -8.49% and a quarterly a decrease of -18.05%. The volatility ratio for the week is 10.37%, and the volatility levels for the last 30 days are 7.38% for Sutro Biopharma Inc (STRO). The simple moving average for the past 20 days is -7.88% for STRO’s stock, with a -13.86% simple moving average for the past 200 days.
Analysts’ Opinion of STRO
Many brokerage firms have already submitted their reports for STRO stocks, with BofA Securities repeating the rating for STRO by listing it as a “Buy.” The predicted price for STRO in the upcoming period, according to BofA Securities is $12 based on the research report published on May 08, 2024 of the current year 2024.
Deutsche Bank, on the other hand, stated in their research note that they expect to see STRO reach a price target of $12. The rating they have provided for STRO stocks is “Buy” according to the report published on November 09th, 2023.
Oppenheimer gave a rating of “Outperform” to STRO, setting the target price at $10 in the report published on October 06th of the previous year.
STRO Trading at -8.41% from the 50-Day Moving Average
After a stumble in the market that brought STRO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.72% of loss for the given period.
Volatility was left at 7.38%, however, over the last 30 days, the volatility rate increased by 10.37%, as shares sank -7.01% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.58% lower at present.
During the last 5 trading sessions, STRO fell by -17.07%, which changed the moving average for the period of 200-days by -20.51% in comparison to the 20-day moving average, which settled at $3.74. In addition, Sutro Biopharma Inc saw -19.58% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at STRO starting from Vasquez Nicki, who sale 12,185 shares at the price of $5.00 back on Jan 29 ’24. After this action, Vasquez Nicki now owns 12,803 shares of Sutro Biopharma Inc, valued at $60,925 using the latest closing price.
Stock Fundamentals for STRO
Current profitability levels for the company are sitting at:
- -0.81 for the present operating margin
- 0.59 for the gross margin
The net margin for Sutro Biopharma Inc stands at -0.77. The total capital return value is set at -0.41. Equity return is now at value -110.89, with -28.06 for asset returns.
Based on Sutro Biopharma Inc (STRO), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at -4.25. The debt to equity ratio resting at 0.22. The interest coverage ratio of the stock is -6.75.
Currently, EBITDA for the company is -67.92 million with net debt to EBITDA at 1.35. When we switch over and look at the enterprise to sales, we see a ratio of 0.83. The receivables turnover for the company is 24.19for trailing twelve months and the total asset turnover is 0.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.09.
Conclusion
To put it simply, Sutro Biopharma Inc (STRO) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
